@FierceBiotech: After death, some stem cells remain alive for days. More | Follow @FierceBiotech
@RyanMFierce: Human Genome Sciences sets deadline of July 16 for acquisition offers, but not sure how that motivates non-GSK buyers. More | Follow @RyanMFierce
> The BIO convention is expected to draw more than 15,000 people to Boston next week, less than the more than 22,000 who attended the meeting in the hub 5 years ago. Organizers blame the economy for the lower attendance this year. Article
> Bay State officials aim to make use of the BIO conference vehicle to drive further growth in the state's biotech sector. Report
> The Myelin Repair Foundation has gone the stem cell route in a pioneering Phase I trial for treating multiple sclerosis. Release
Pharma News
@FiercePharma: NICE tells Roche Zelboraf is too expensive. More | Follow @FiercePharma
> Feds nail Internet pharmacy operator for fake drugs. News
> HGS sets deadline for bids: Come and get it! Story
> Drugmakers line up for tsunami of diabetes. More
Medical Device News
@FierceMedDev: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @FierceMedDev
> U.K. regulators cracking down on sale of fake devices. More
> Will the device tax cost lives? Story
> FDA investigates Fresenius over kidney dialysis controversy. Article
> GAO: Orthopedic implantable device admission rates soar. More
And Finally… Viacyte, a San Diego biotech researching cell therapy for diabetes, has named Dr. Paul Laikind its president and CEO. Item